摘要
目的探讨英夫利昔单抗与硫唑嘌呤联用治疗克罗恩病的临床疗效。方法 68例克罗恩病患者,根据治疗方法不同,将其分为两组,对照组32例,观察组36例,对照组单独采用英夫利昔单抗进行治疗,观察组采用英夫利昔单抗与硫唑嘌呤联用治疗,两组患者均在治疗第24周末统计患者克罗恩病活动指数(CDAI),评价患者的治疗效果。结果治疗后对照组总有效率为78.13%,观察组总有效率为91.67%,两组比较差异有统计学意义(P<0.05)。两组患者治疗期间均发生了不良反应(迟发型超敏反应、肝功能异常及胃肠道反应等),但并未影响治疗,经比较,差异无统计学意义(P>0.05)。结论英夫利昔单抗与硫唑嘌呤联用治疗克罗恩病临床疗效确切,值得推广应用。
Objective To investigate the clinical effect of infliximab combined with azathioprine in the treatment of Crohn＇s disease. Methods A total of 68 patients with Crohn＇s disease were divided by different treatment methods into two groups, as control group with 32 cases and observation group with 36 cases. The control group received infliximab alone for treatment, and the observation group received infliximab combined with azathioprine. Crohn＇s disease activity index（CDAI） of the two groups was summarized in 24 weeks of treatment, and curative effects were evaluated. Results After treatment, the total effective rate of the control group was 78.13%, and that of the observation group was 91.67%. The difference between the two groups had statistical significance（P〈0.05）. Both groups had adverse reactions（delayed type hypersensitivity, abnormal liver function, and gastrointestinal reaction） during treatment without influencing treatment. Their difference had no statistical significance（P〈0.05）. Conclusion Combination of infliximab and azathioprine provides precise effect in treating Crohn＇s disease, and it is worthy of promotion and application.
出处
《中国实用医药》
2015年第18期66-67,共2页
China Practical Medicine
